Oncology Key lessons from EHA 2026: Translating evidence into impact Across four days in Sweden, EHA 2026 offered a clear view of the future of blood cancer care.
Patients ASCO 2026: New hope in AL amyloidosis, with Dr Hans Lee A phase 1/2 trial in AL amyloidosis saw 100% of patients obtaining at least a very good partial response with 90% obtaining a complete response.
News ASCO26: Could AL amyloidosis see a new crop of therapies? Trials of AstraZeneca's anselamimab and Regeneron's Lynozyfic could deliver much-needed new therapeutic options for rare disease AL amyloidosis.
News Bayer plans filings for cardiac amyloidosis imaging agent Armed with new phase 3 data, Bayer is preparing to file a PET imaging agent that could accelerate the diagnosis of cardiac amyloidosis.
News AstraZeneca sifts for efficacy crumbs in amyloidosis trial AstraZeneca's light chain (AL) amyloidosis candidate anselamimab has failed a phase 3 readout, but showed efficacy in a patient subgroup.
News In U-turn, NICE backs first drug for AL amyloidosis Almost four years after it was approved in Europe to treat the incurable rare disease systemic amyloid light-chain (AL) amyloidosis, Johnson & Johnson’s Darzalex has b
News Vogenx surpasses expectations with $81M IPO With $81.3 million raised, Vogenx is the latest in a staggering summer of biotech IPOs. But the queue past this point looks thin.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
